Sign In
Buy ARKG
$33.15
-0.260 (-0.778%)
At Close: Jun 08, 2026
3 Biotech ETFs Overdue for a Bounce
02:45pm, Tuesday, 19'th Mar 2024
Growth-focused investors may wish to set their sights on the hard-hit biotech stocks scene as rates begin to retreat, negative momentum settles and the industry catches a bit of a break for once. Of c
Cathie Wood Speaks, ARK Investors Should Listen
09:37pm, Saturday, 09'th Mar 2024
Cathie Wood criticizes the US Federal Reserve for its monetary policy mistakes and argues that deflation, not inflation, should be the concern. Wood presents charts showing that technologically driven
China-focused ETFs struggle amid fears of another regulatory ‘crackdown'
03:23pm, Thursday, 18'th Jan 2024
Hi! This week's ETF Wrap funds looks at China-focused funds that are struggling in 2024, with Clocktower's chief strategist Marko Papic providing his take on concerns tied to the country.
5 Best ETF Areas of Last Week
09:01am, Wednesday, 27'th Dec 2023
Wall Street was upbeat last week.The optimism surrounding the likely Fed rate cuts in 2024 aided the rally in the market, barring some occasional dips.
VIDEO: ETF of the Week: ARK Genomic Revolution ETF (ARKG)
11:50am, Monday, 18'th Dec 2023
On this episode of the “ETF of the Week” podcast, Tom Lydon discussed the ARK Genomic Revolution ETF (ARKG) with Chuck Jaffe of “Money Life.” The pair talked about several topics regarding the
Sector ETFs to Gain as Fed Stays Put, Sees Deeper Rate Cuts in 2024
02:17pm, Thursday, 14'th Dec 2023
The Federal Reserve held its benchmark interest rate steady at a range of 5.25%-5.50% on Dec 13. However, the Fed hinted at three 25-bp rate cuts next year.
ETF of the Week: ARK Genomic Revolution ETF (ARKG)
02:04pm, Thursday, 14'th Dec 2023
VettaFi's vice chairman Tom Lydon discussed the ARK Genomic Revolution ETF (ARKG) on this week's “ETF of the Week” podcast with Chuck Jaffe of “Money Life.” For more news, information, and an
VettaFi Voices On: The Outlook for 2024
03:08pm, Friday, 08'th Dec 2023
Good morning, VettaFi Voices! We are a week out from the VettaFi 2024 Market Outlook Symposium on December 14, which will feature a range of ETF industry leaders discussing their expectations for diff
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
08:30am, Monday, 04'th Dec 2023
Genomic medicine is predicted to become a multi-billion-dollar industry. Even so, this market will probably take years to mature, and risks abound as a result.
1 Cathie Wood Stock That Could Deliver Life-Changing Returns in 10 Years
07:45am, Thursday, 30'th Nov 2023
Cathie Wood is known for investing in cutting-edge innovators. Her ARK Genomic Revolution ETF owns several gene-editing companies, but Prime Medicine might be the best of the bunch.
Analyzing ARKG's Trading Activity In Q3
11:31pm, Wednesday, 22'nd Nov 2023
ARK Genomic Revolution ETF focuses on genomic innovation in sectors such as healthcare, information technology, and energy. The fund's buying and selling activity gives us clues about the degrees of c
The 3 Best Gene Editing Stocks on the Frontier of Medicine
05:43pm, Monday, 20'th Nov 2023
Some of the best gene editing stocks could soon see a massive boost. In just days, the U.S. FDA could approve the first gene-editing treatment of sickle cell disease (SCD) from CRISPR Therapeutics�
Best-Performing ETFs of Last Week
09:01am, Monday, 20'th Nov 2023
Wall Street was upbeat last week. The reason behind the market rally was cooling inflation.
VettaFi Voices On: Accessing Disruptive Innovation
04:04pm, Friday, 17'th Nov 2023
Good Morning, VettaFi Voices! Disruptive innovation is a popular topic, and it encompasses everything from bitcoin and cryptocurrency to electric vehicles to artificial intelligence.
1 Cathie Wood Stock to Buy Hand Over Fist Right Now
08:00am, Thursday, 09'th Nov 2023
Cathie Wood's ARK Invest family of ETFs focuses on the interrelated concepts of innovation and disruption. Verve Therapeutics, a holding in two of her better-known ETFs, appears primed for a sustained
